About Cocrystal Pharma
We have identified promising antiviral therapeutics that target the replication process of influenza viruses, noroviruses and coronaviruses, including SARS-CoV-2 and its variants. We are conducting a Phase 2a human challenge study targeting pandemic and seasonal influenza A with an oral PB2 inhibitor, and a Phase 1 study with the first dual coronavirus-norovirus oral antiviral. Preparations are underway to begin clinical testing of our inhaled PB2 influenza A inhibitor as a therapeutic and prophylactic agent.